doxazosin Side Effects
Also known as: Cardura
Analysis of 27,049 adverse event reports submitted to the FDA from 2003 to 2025.
Total Reports
27,049
Death-Related
2,269
8.4% of reports
Hospitalizations
11,467
42.4% of reports
Top Indication
Product Used For Unknown Indication
Most Reported Adverse Reactions
Who Reports Side Effects
Gender Distribution
Age Distribution
Reporting Trend by Year
Reactions in Death Reports
Top reactions reported in 2,269 reports where death was an outcome. These are voluntarily reported and do not establish causation.
| Reaction | Reports |
|---|---|
| DEATH | 677 |
| RENAL FAILURE | 165 |
| DYSPNOEA | 163 |
| PNEUMONIA | 140 |
| ACUTE KIDNEY INJURY | 136 |
| CARDIAC ARREST | 100 |
| ASTHENIA | 98 |
| CHRONIC KIDNEY DISEASE | 97 |
| MYOCARDIAL INFARCTION | 95 |
| SEPSIS | 93 |
| ANXIETY | 91 |
| PULMONARY EMBOLISM | 86 |
| COMPLETED SUICIDE | 82 |
| FATIGUE | 82 |
| HYPOXIA | 78 |
| CARDIAC FAILURE CONGESTIVE | 77 |
| CONDITION AGGRAVATED | 74 |
| ARTERIOSCLEROSIS | 73 |
| RESPIRATORY FAILURE | 73 |
| END STAGE RENAL DISEASE | 70 |
Reactions in Hospitalization Reports
Top reactions in 11,467 reports where hospitalization was an outcome.
| Reaction | Reports |
|---|---|
| DYSPNOEA | 825 |
| ACUTE KIDNEY INJURY | 806 |
| HYPOTENSION | 613 |
| FALL | 522 |
| DIARRHOEA | 514 |
| PNEUMONIA | 505 |
| VOMITING | 501 |
| DIZZINESS | 473 |
| ANAEMIA | 471 |
| DRUG INTERACTION | 451 |
| ASTHENIA | 444 |
| HYPERTENSION | 439 |
| NAUSEA | 434 |
| RENAL FAILURE | 420 |
| FATIGUE | 409 |
| SYNCOPE | 407 |
| HYPONATRAEMIA | 389 |
| DRUG INEFFECTIVE | 359 |
| CONDITION AGGRAVATED | 357 |
| ATRIAL FIBRILLATION | 345 |
Nearby — Related Medications
What the FAERS Data Reveals About doxazosin Side Effects
The FDA Adverse Event Reporting System (FAERS) contains 27,049 voluntary reports linked to doxazosin and its brand equivalents (Cardura), spanning 2003 through 2025. Of those, 2,269 (8.4%) listed death as an outcome and 11,467 (42.4%) involved hospitalization. The most common indication reported alongside adverse events was Product Used For Unknown Indication.
Demographic breakdowns help contextualize who is being exposed to the drug. Of reports with known sex, 35% were female and 65% male; age distribution skews toward 75+, with 7,693 reports in that bracket. The single most reported reaction is dyspnoea with 1,479 submissions, followed by dizziness and fatigue.
FAERS is a signal-detection tool, not a scorecard. Reports are voluntary, and a single case may list multiple suspect drugs, so numbers above should not be read as incidence rates or per-patient risk. Widely prescribed drugs naturally accumulate more reports than niche therapies even when individual risk is low. These aggregates are useful for spotting patterns that merit further pharmacovigilance, not for choosing between medications. This page is for educational reference only and is not medical advice — speak with a licensed clinician about any side-effect concerns.
Read our methodology — how this data is sourced, computed, and verified.